MGMT and glioblastoma: Exploitation of direct repair has clear clinical implications in glioblastomas; in fact, a randomized clinical trial by Hegi et al.85 demonstrated that glioblastoma patients with a methylated MGMT promoter had better outcomes after treatment with temozolomide, an alkylating agent, although a smaller effect was still observed in patients without MGMT promoter methylation.